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BACKGROUND
SATB2 (special AT-rich sequence-binding protein 2) was 
originally identified as a gene disrupted by breakpoints in two 
different de novo apparently balanced chromosomal rearrange-
ments involving distal 2q32 in unrelated girls with cleft palate, 
a distinctive facial appearance, and intellectual disability.1,2 It is 
now recognized that de novo heterozygous single-nucleotide 
variants in SATB2 are one of the most common causes of syn-
dromic ID, accounting for ~0.3% of all analyzed affected indi-
viduals in the Deciphering Developmental Disorders (DDD) 
study.3 The distinct site-specific and stage-specific expression 
pattern of Satb2 in embryonic mouse palatal shelves suggested 
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Purpose: To characterize features associated with de novo mutations 
affecting SATB2 function in individuals ascertained on the basis of 
intellectual disability.
Methods: Twenty previously unreported individuals with 19 
different SATB2 mutations (11 loss-of-function and 8 missense 
variants) were studied. Fibroblasts were used to measure mutant 
protein production. Subcellular localization and mobility of wild-
type and mutant SATB2 were assessed using fluorescently tagged 
protein.
Results: Recurrent clinical features included neurodevelopmen-
tal impairment (19/19), absent/near absent speech (16/19), normal 
somatic growth (17/19), cleft palate (9/19), drooling (12/19), and 
dental anomalies (8/19). Six of eight missense variants clustered in 
the first CUT domain. Sibling recurrence due to gonadal mosaicism 
was seen in one family. A nonsense mutation in the last exon resulted 
in production of a truncated protein retaining all three DNA-bind-
ing domains. SATB2 nuclear mobility was mutation-dependent; 
p.Arg389Cys in CUT1 increased mobility and both p.Gly515Ser in 
CUT2 and p.Gln566Lys between CUT2 and HOX reduced mobility. 
The clinical features in individuals with missense variants were indis-
tinguishable from those with loss of function.
Conclusion: SATB2 haploinsufficiency is a common cause of 
 syndromic intellectual disability. When mutant SATB2 protein is 
produced, the protein appears functionally inactive with a disrupted 
pattern of chromatin or matrix association.
Genet Med advance online publication 2 February 2017
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a direct role in the etiology of both cleft palate and ID. This was 
subsequently confirmed by targeted inactivation of Satb2 in 
mice, which demonstrated a dosage-sensitive role for the gene 
product in midline craniofacial patterning, osteoblast differen-
tiation,4 and determining the fates of neuronal projections in 
the developing cerebral cortex.5,6
The first intragenic point mutation in SATB2 was reported 
in 2007, by Leoyklang et al.,7 in a 36-year-old man with a het-
erozygous nonsense mutation in SATB2 associated with a cleft 
palate, generalized osteoporosis, profound intellectual disabil-
ity, epilepsy, and a jovial personality. Other de novo structural 
chromosomal anomalies, including SATB2 disruptive break-
points,8,9 intragenic deletions,10 and intragenic duplications,11 
provided further evidence for an association with cleft pal-
ate and cognitive impairment. More recently, genome-wide 
sequencing studies have reported seven additional individuals 
with de novo heterozygous single-nucleotide variants in SATB2 
with phenotypes that overlap that previously associated with 
haploinsufficiency.12–14
The SATB2 transcription unit spans 195.6 kb of genomic 
DNA (chr2:200,134,223-200,329,831 hg19) encoding a DNA-
binding protein with a remarkably high level of conservation in 
primary sequence throughout vertebrate evolution.15 The gene 
lies telomeric to a gene desert containing multiple cis-regula-
tory elements essential for normal developmental expression of 
SATB2.16 CUT is a class of divergent homeodomain first identi-
fied in the cut protein encoded by the Drosophila melanogaster 
gene ct. SATB2 has two CUT domains (amino acids 352–437 
and amino acids 482–560) and a classic homeodomain (amino 
acids 614–677).2
We report molecular and phenotypic features of 20 pre-
viously unreported individuals with heterozygous de novo 
probable loss-of-function mutations in SATB2 identified by 
whole-exome sequencing (WES). Comparing the clinical fea-
tures in these individuals with those from previously reported 
individuals has enabled further delineation of the SATB2-
associated syndrome. The eight individuals with missense vari-
ants in this gene have clinical features indistinguishable from 
those with clear loss-of-function mutations. One of the families 
shows evidence for gonadal mosaicism as the cause of sibling 
recurrence of an apparently de novo variant in SATB2.
MATERIALS AND METHODS
Subjects and clinical data
Sixteen of the 20 affected individuals included in this study 
were identified via trio-based WES as part of the DDD study 
(http://www.ddduk.org) Study. This study was approved by 
the UK Multicentre Research Ethics Committee under refer-
ence 10/H0305/83, and written consent was obtained from all 
participating families. Quantitative and categorical phenotypic 
data were extracted from the DDD patient information data-
base. Non-DDD case information was supplied by the refer-
ring clinician. Two affected individuals were identified via WES 
analyses performed within separate clinical genetics labora-
tories; KAROL1 was referred to the Department of Clinical 
Genetics, Karolinska University Hospital, for dysmorphologi-
cal and diagnostic evaluation. Written informed consent for 
inclusion in the study and consent for the publication of photo-
graphs were obtained from the legal guardians, with the study 
approved by the regional ethics committee in Stockholm. The 
remaining two individuals (29089 and 29090) were siblings in 
whom the same mutation was identified via a custom solution 
capture-targeted resequencing analysis of a large cohort with 
previously unexplained intellectual disability representing part 
of the GOLD study (Genetics of Learning Difficulties).
WES and targeted resequencing
Details of the clinical ascertainment, WES strategy, variant call-
ing, and filtering pipelines used in the DDD study are described 
elsewhere.17 Briefly, genomic DNA from affected individuals and 
their parents was extracted from blood or saliva and subjected 
to target capture using Agilent SureSelect 55MB Exome Plus 
and sequenced on Illumina HiSeq. De novo sequence variants 
were identified using DeNovoGear (https://github.com/deno-
vogear) and the effect of each genomic variant was predicted 
with the Ensembl Variant Effect Predictor (grch37.ensembl.
org/Homo_sapiens/Tools/VEP). For individual KAROL1, WES 
was performed in a family trio-based study using Illumina 
technology (Illumina, San Diego, CA). The sequencing was 
performed at Oxford Gene Technology and sequence data 
were returned and analyzed using software supplied by Oxford 
Gene Technology. Prior to the WES analysis array, comparative 
genomic hybridization was performed for all individuals with 
normal results. Details of the clinical ascertainment and targeted 
exome sequencing, variant calling, and filtering pipeline used in 
the GOLD study, a subset of the UK10K project, to identify sib-
lings with mutations are described elsewhere.18 All mutations 
have been validated at least once as de novo using independent 
sequencing technologies (Sanger sequencing and/or targeted 
pull-down with next-generation sequencing).
3D modeling of mutations
3D modeling of structural effects was performed using the 
mutate_model script in MODELLER19 on available solu-
tion structures for residues 350–437 (RCDB PDB 1WIZ) for 
the CUT1 domain and 473–560 (RCDB PDB 2CSF) for the 
CUT2 domain. The resulting models were visualized using a 
SWISS-PdbViewer.20
Average face analysis
To visualize the characteristic facial features of patients with 
shared mutations in the same gene, we generated realistic, de-
identified average faces from unstandardized 2D facial pho-
tographs taken at clinic appointments. This was achieved by a 
fully automated, three-step algorithm that detects the location 
of a face within an image, identifies the locations of 36 facial 
feature points on the face, and creates composites from mul-
tiple faces using their respective facial feature points. Faces 
were detected using a discriminately learned deformable parts 
model detector.21 The resulting detection box was used to 
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initialize the facial feature point annotation algorithm. We used 
the Supervised Descent Method approach detailed in ref. 22, 
which we trained using a data set of 3,100 manually annotated 
images.23 The resulting annotations were used to create a face 
mesh for each using Delaunay triangulation.
Our previously reported face averaging algorithm23,24 was 
improved on with the introduction of left–right facial asym-
metry preservation and better de-identification of individuals. 
The averaging algorithm was initialized with a target face mesh, 
which was created by averaging the facial feature point con-
stellations for 2,000 healthy individuals. The face mesh of each 
patient was aligned to this target mesh with respect to the points 
across the middle of the face (from forehead to chin). We then 
compared the Euclidean distances between each feature point 
pair on the patient’s mesh and the target. The relative difference 
between points on the right and left sides of the face was used 
as a measure of left–right facial asymmetry and faces were mir-
rored such that the side with greater deviance from the target 
mesh was on the same side for all patients. Once the asymme-
tries were taken into account, we created average face meshes 
for each group of patients that shared a mutation. The average 
face was created by morphing the image of each patient’s face 
onto this average face mesh. To avoid biases toward individu-
als with multiple images, we computed an average face for each 
patient and used these personal averages to compute the final 
average face. Finally, to avoid variances in illumination between 
images, which could cause any image in the composite to domi-
nate, we normalized the pixel values within the face to an aver-
age value across all faces for each average.
Plasmids, cell culture, and Photobleaching Experiments
Full-length human SATB2 cDNA was amplified from the 
human fetal brain cDNA library. The polymerase chain reac-
tion product was cloned downstream of green fluorescence pro-
tein (GFP) in the Gateway pcDNA-DEST53 Vector according 
to the manufacturer’s protocol, resulting in N-terminal fusion 
protein. Site-directed mutagenesis was used to make mutant 
constructs. HeLa and human fibroblast cell lines were grown at 
37 °C in 5% CO2 in Dulbecco’s modified Eagle’s medium con-
taining 10% fetal bovine serum and 1% penicillin/streptomy-
cin. Cells were seeded onto glass-bottom dishes (Mattek) and 
transfections were performed using Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s instructions. Up 
to 0.5 µg of each SATB2 construct was used per transfection. 
Media was substituted for Hank’s balanced salt solution 18–24 h 
after transfection and imaging was performed using a Nikon 
A1R confocal microscope equipped with the Nikon Perfect 
Focus System using a 60× oil immersion objective with a 1.4 
numerical aperture. Using bleaching experiments, the pinhole 
was set to airy2 and digital zoom parameters were kept constant 
for each cell type. GFP was excited using a 488-nm laser, and 
emitted light was collected at 500–550 nm. Dishes of control 
and mutant cells were alternated over the course of imaging. 
Cells expressing constructs at comparable levels, with recorded 
fluorescence intensity within the dynamic range of the detector 
at similar gain settings, were selected for analysis. Data shown 
are representative of three independent experiments (n ≥ 21 
cells per SATB2 construct).
Cell lines, fractionation, western blotting, and antibodies
Stable cell lines were generated by Flp recombinase– mediated inte-
gration using HEK-293-Flp-In T-REx host cells (ThermoFisher) 
transfected with pcDNA5/FRT/TO-EGFP (EGFP-SATB2 
or Mutant SATB2) and pCAGGS-Flp. Transfected cells were 
selected using 5 μg/ml blasticidin and 400 μg/ml hygromycin 
and protein expression was induced with 1 μg/ml tetracycline 
treatment. Subcellular fractions were prepared according to the 
method of de Seo et al.25 HEK-293-Flp-In T-REx expressing full-
length or mutant EGFP-SATB2 were treated with 0.5% Triton 
X-100 in cytoskeleton buffer (10 mmol/l PIPES (piperazine-
N,N’-bis(2-ethanesulfonic acid)), pH 6.8, 100 mmol/l NaCl, 
300 mmol/l sucrose, 3 mmol/l MgCl2, and 1  mmol/l EGTA) 
supplemented with 1 mmol/l phenylmethanesulfonyl fluoride 
and 1× protease inhibitor mixture (Roche Applied Science) 
on ice. The supernatant was recovered after centrifugation and 
referred to as the soluble fraction. The insoluble fraction was 
suspended in cytoskeleton buffer and treated with 20  units of 
DNase I (Roche Applied Science) for 15 min at 37 °C; ammo-
nium sulfate was added to a final concentration of 0.25 M. The 
soluble material was referred to as the chromatin fraction, and 
the insoluble fraction was washed with 2 M NaCl. The remain-
der (nuclear matrix fraction) was dissolved in 8 M urea and 
10 mmol/l Tris-HCl, pH 8.0. The same proportion of each frac-
tion was analyzed by western blot using anti-GFP antibody (sc-
8334; Santa Cruz Biotechnologies, Dallas, TX). Anti-histone 
H3 (ab1791; Abcam, Cambridge, UK) and anti-lamin (sc-6216; 
Santa Cruz Biotechnologies) antibodies were used as chromatin 
and matrix fraction loading control. Immunoblotting was per-
formed according to the standard protocol. Protein extracts from 
control and patient human fibroblast cell lines were mixed with 
4× loading dye (Invitrogen), boiled, and separated on Novex 
4–12% Bis-Tris Protein Gels (Invitrogen), followed by transfer 
onto polyvinylidene fluoride membranes. An affinity-purified 
antibody raised against an N-terminal His-tag fusion of the 
C-terminal half of human SATB2 (a.a. 329–733) was raised in 
rabbits as previously described.16 Enhanced chemiluminescence 
reagents (Amersham) were used for antibody detection. All cell 
lines were checked for mycoplasma contamination prior to use.
RESULTS
Consequences of disease-associated de novo mutation in 
SATB2
Eleven of the 19 de novo SATB2 variants reported here were 
predicted to be clearly disruptive to protein production, result-
ing in loss of function (Figure 1a, bottom panel). Two of 19 
variants disrupted an essential splice site consensus sequence: 
one affecting the donor (5’) site at the end of exon 5 and one 
altering the acceptor (3’) site at the start of exon 8. Four of 19 
were nonsense (stop gained) variants: one in exon 4, two in 
exon 8, and one in the last exon (exon 11). We identified 5/19 
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as frameshift variants, with each occurring 5’ to the last intron 
exon boundary of the gene (significant).
Eight of the variants predicted nonsynonymous changes in 
the open reading frame (Figure 1a, top panel). Seven of eight 
were located in the center of a CUT domain: six in CUT1 and 
one in CUT2. Each of the CUT domain variants had SIFT 
and PolyPhen scores that predicted a significant perturbation 
in protein function. The final missense variant (p.Glu566Lys) 
was in the region between the CUT2 and HOX domain. SIFT 
and PolyPhen predicted this variant to be tolerated or benign. 
Using Exome Aggregation Consortium data, we created den-
sity plots of the number of nonsynonymous variants that have 
been observed in the open reading frame in a population that 
was not selected for developmental disease (Figure 1a, middle 
panel). No variants were observed in the central portions of 
either CUT domain, suggesting the operation of purifying 
selection within the human population at these regions. There 
was evidence for constraint within the HOX domain, but the 
pattern was less striking on the density plot.
Evidence for gonadal mosaicism in SATB2 de novo 
mutations
One of the essential splice variants (c.598-2 A>G) was identi-
fied as a heterozygous variant in two brothers (29089 and 29090) 
Figure 1 SATB2 mutation spectrum and consequence. (a) The relative positions of the de novo mutation identified in this article are indicated in a cartoon 
representation of the SATB2 wild-type protein, which includes the location of the DNA-binding domains. Below the protein diagram are the mutations that are 
predicted to result in disruption of the open reading frame. The mutations are color-coded by type: nonsense (red), frameshift (purple), and essential splice site (orange). 
The intron–exon boundaries of the gene encoding the protein are shown as vertical gray lines and the exon number given between these. Above are the missense 
variants, which have been color-coded to represent the predicted effect of the residue substitution. Immediately above the protein cartoon is a density plot representing 
the position of all missense variants seen more than once in the Exome Aggregation Consortium database. (b) The family structure and cognate chromatographs are 
shown of the family with apparent gonadal mosaicism. The affected boys (II:2 29089 and II:4 29090) share the same essential splice site mutation, which is absent in 
both parents (I:1 and I:2). (c) Photograph of a western blot of protein derived from cultured fibroblasts of two unrelated control individuals and case 14 with a nonsense 
mutation in the final exon using an antibody made for the C-terminal region of SATB2. A pre-stained protein ladder (Invitrogen LC5925) was used to assess the size 
of the bands. The same membrane was imaged using both white light and chemiluminescence and the cropped ladder image was size matched and aligned to the 
immunoblot. The expected SATB2 band of ~80 kDa is seen in all three, with a band of unknown identity above this. A lower band, consistent with the production of 
the 692-amino-acid C-terminally truncated version on SATB2, is seen in case 14 but not in the control.
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who had been recruited to the GOLD study with suspected 
X-linked intellectual disability. Subsequent analysis of the fam-
ily revealed normal sequence at this base in peripheral blood–
derived DNA from both parents. Biological relationships within 
the family were confirmed using a panel of highly informative 
single-nucleotide polymorphisms. These findings indicated that 
gonadal mosaicism was present in one of the parents. We were 
not able to determine the parental origin of the mutation because 
of the lack of informative markers on the parental alleles.
Stop-gain in the last exon escapes nonsense-mediated 
decay
The stop-gain mutation in the last exon would be expected to 
escape nonsense-mediated decay. The predicted protein would 
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have all three DNA-binding domains intact but would lack the 
final 41 amino acids. To determine whether this protein is pro-
duced, we established a fibroblast cell line from a skin biopsy 
derived from the affected individual. Western blot using protein 
extract from these fibroblasts and two control fibroblast lines 
showed the presence of the expected SATB2 band of ~80 kDa in 
all three cell extracts (Figure 1c). An additional, smaller band 
was present only in the patient-derived fibroblasts. The size of 
this band was consistent with the predicted 692aa protein prod-
uct of the mutant cDNA. This supports the hypothesis that this 
mutant mRNA escapes nonsense-mediated decay.
SATB2 missense mutations alter the DNA-binding domain 
structure and nuclear mobility
The available crystal structures for CUT1 (1WIZ) and CUT2 
(2CSF) were used to predict the effect of the missense variants 
on the domain structure using the MODELLER program. Each 
of the mutations was predicted to result in a structural change 
with alterations in C-terminal boundary of alpha helix 2 and 
the N-terminal boundary of helix 3 in the affected CUT domain 
(Figure 2a,b).
To assess the effect of the missense variants on subcellular 
localization, we created plasmids expressing wild-type and 
mutant SATB2 cDNA fused at its N-terminus to a fluorescent 
marker protein (GFP). Transient transfection of these con-
structs was performed to determine the effect of the mutations 
on subcellular localization. Each of the mutant and wild-type 
fusion proteins was efficiently targeted to the nucleus; however, 
specific patterns of nuclear localization were apparent. The 
p.Arg389Cys change gave a more diffuse pattern than the wild-
type, p.Gly515Ser, or p.Gln566Lys substitutions (Figure 2e). 
A construct that contained only the region of the SATB2 
N-terminal of the DNA-binding domains was targeted to a rel-
atively small number of discrete nuclear foci (Figure 2d,e). As 
an indicator of chromatin association dynamics, we used pho-
tobleaching of the exogenous fusion proteins within the nuclei 
of transfected cells. This technique uses a laser to irreversibly 
bleach the tagged fluorescent protein in a small area within the 
nucleus and then measures the speed and completeness of the 
recovery of fluorescence in the bleached area as an indication 
of the kinetics of protein association with chromatin or nuclear 
matrix. This indicated that the CUT1 change was associated 
with the highest level of residual fluorescence after recurrent 
photobleaching and a recovery rate similar to that of the wild 
type. Mutations affecting p.Gly515 and p.Gln566 had profiles 
similar to those with the most prominent loss of fluorescence 
following recurrent photobleaching and the slowest recovery 
(Figure 2f,g).
We then produced tetracyclin-inducible stable HEK293 cell 
lines for the GFP-tagged wild type and the same missense 
mutations. This enabled us to use cell fractionation tech-
niques to look for alterations in the distribution of each protein 
between the soluble, chromatin, and nuclear matrix (Figure 2c). 
This showed a marked increase in the proportion of the 
p.Arg389Cys protein in the soluble fraction, although chro-
matin associated protein was still seen. A lower proportion of 
the total p.Gln566Lys protein was matrix-associated. With this 
assay, no other obvious differences were apparent.
Genotype–phenotype correlations
Three approaches were taken to assess the phenotypic character-
istics of the individuals with SATB2 mutations described here. 
The first compared the facial appearance of published individuals 
with SATB2-associated disease with that of the affected individu-
als presented here (in whom facial images were available) by cre-
ating an “average” face for each group (Figure 3a,b). This analysis 
used standard 2D clinical photographs. Both faces were similar, 
with the main difference being that the individuals reported here 
appeared younger. The dysmorphism was subtle, with a small 
mouth and mild facial asymmetry seen in both images. All indi-
viduals submitted to DDD are coded using the human pheno-
type ontology. We used a heat map to display terms that had been 
used more than once in this group of individuals (Figure 3c). No 
differences were apparent between the individuals in DDD with 
missense variants or those predicted to have clear loss of func-
tion. Finally, aggregation of quantitative and categorical aspects 
of the phenotype on the basis of the mutation type revealed no 
significant differences between the missense and loss-of-function 
groups (Supplementary Table S1 online).
DISCUSSION
The individuals reported here were ascertained via diagnos-
tic sequencing approaches that do not require a priori suspi-
cion of any specific clinical syndrome to be available. Since 
Figure 2 Effect of mutation within DNA-binding domains of SATB2. In silico predictions of the structural effects of missense mutations affecting 
CUT1 (a) or CUT2 (b) are shown. In each case, the boundaries of alpha helixes 3 and 2 have been altered (red arrows). The position of the cognate mutation 
within the DNA-binding domain is shown on a cartoon of the SATB2 protein in d. (c) Western blot analysis of fractionated HEK293 cells with Tetracyclin (TET) 
inducible expression of GFP-tagged mutant and wild-type SATB2. Most SATB2 is attached to the matrix. The CUT1 missense mutation results in a marked 
increase in the proportion of the protein in the soluble fraction. The missense mutation between CUT2 and HOX shows apparent reduced levels of matrix 
association. Antibodies against lamin and histone are presented to show that the fractionation has worked. (d) The gray-shaded box represents the protein 
product of an artificial control mutation that has been made in the cDNA of SATB2 to create a peptide with none of the DNA-binding domains. This is termed 
the “N-terminal region.” (e) Confocal photomicrographs of cells transiently transfected with plasmids containing wild-type and mutant GFP-tagged SATB2 
cDNA under the control of a ubiquitous promoter. The mutation is shown above each photograph. The wild-type, p.Gly515Ser, and p.Gln566Lys cDNAs all 
produce a granular pattern of fluorescence within the nucleus, the N-terminal regions show a punctate pattern, and the p.Arg389Cys shows a glassy diffuse 
pattern. (f, g) Representative images of cells from independent transient transfections of the wild-type, p.Arg389Cys, p.Gly515Ser, and p.Gln566Lys cDNAs 
to assess fluorescence loss and recovery after multiple photobleaching using regions of the nucleus (illustrated for this experiment by the red squares on the 
photomicrographs). This graph shows quantitation of the fluorescence after each photobleach and recovery. The error bars represent standard deviations for 
the measurements at each time point.
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2010, trio-based next-generation sequencing approaches have 
transformed our understanding of the generic architecture 
of moderate to severe global neurodevelopmental disability,26 
with the proportion of individuals in whom a diagnostic vari-
ant can be confidently assigned approaching 40% in previously 
undiagnosed individuals. The most common genetic—and 
analytically tractable—mechanism is de novo mutation with 
protein-altering or haploinsufficient effects. This approach to 
diagnosis enables a relatively unbiased picture of the phenotype 
associated with each gene/genetic mechanism to be obtained. 
SATB2 is among the most commonly reported genes in the 
DDD study, accounting for ~0.3% (14/4294) of all analyzed 
individuals.
For SATB2, the core associated clinical features have remained 
remarkably stable since the original individuals were reported 
by two of this article’s authors (H.V.F. and D.R.F.) in 1999.1,2 
These two girls had strikingly similar facial appearances; both 
had cleft palate, normal prenatal and postnatal growth, and 
intellectual disability most strikingly in speech and language 
development. For the individuals reported here, neurodevelop-
mental impairment was the universal method of ascertainment. 
Other recurrent clinical features were normal somatic growth 
in 17/19 affected individuals; 16/19 had absent or near absent 
speech, with drooling reported for 12/19, suggesting that the 
development of normal oral motor coordination may be sig-
nificantly impaired. Close to half of the affected individuals 
(9/19) had cleft palate. Minor dental anomalies were reported 
for 8/19. The behavioral phenotype appeared to show the most 
marked discrepancy within the cohort, with both severe autis-
tic features and friendly/happy personalities being recurrently 
reported. The overall level of intellectual disability was in the 
moderate to severe group. Importantly, no differences could be 
discerned in the range or severity of phenotypes between indi-
viduals with clear loss-of-function mutations and those with 
missense variants, supporting haploinsufficiency as the com-
mon pathogenic mechanism.
To objectively assess the facial appearance associated with 
SATB2, we used recently developed image analysis techniques 
that were previously used for computational assessment of dys-
morphic diagnoses.23,24 The resulting average face created for the 
current and published groups suggests that the facial appear-
ance of younger individuals is similar but more subtle than that 
of the previously reported individuals commonly ascertained 
via cytogenetic analysis. During this analysis, consistent asym-
metry in the face was noted. Asymmetry had previously been 
noted in both the brain and cranium on high-resolution mag-
netic resonance imaging as part of a clinical reassessment of 
one of the original SATB2 individuals.16 Although SATB2 was 
previously implicated in the coordination of scaled growth 
between the upper and lower jaw,27 it is not known to have a 
role in maintaining symmetry.
Although the precise nuclear function of SATB2 is not yet 
clear, it binds DNA in a sequence-specific manner in vivo, 
resulting in gene activation in cis28 and is expressed in a site-
specific and stage-specific manner during development; in light 
of the human and mouse phenotypes associated with hetero-
zygous loss-of-function mutations, it seems reasonable to con-
sider it to be a dosage-sensitive transcription factor. In addition, 
Figure 3 Facial characteristics associated with de novo mutations 
in SATB2. (a) Average face constructed from the available published facial 
images from individuals with de novo mutations in SATB2. (b) Average face 
constructed from facial photographs from 10 of the individuals with the de 
novo mutation in SATB2 reported here. Both images show a small mouth 
with a thin upper lip and facial asymmetry. The asymmetry is subtle and most 
noticeable in the jaw line and corners of the mouth. (c) Heat map of the 
recurrently reported human phenotype ontology terms in the 14 Deciphering 
Developmental Disorders study individuals reported here in whom these 
terms had been systematically collected prior to the molecular diagnosis 
being made.
a
c
b
Drooling
Abnormality of the oral cavity
Cleft palate
Delayed speech and language development
Strabismus
Abnormality of globe location
Abnormality of the hand
Abnormality of the skin
Figure 4 Provisional model for the role of SATB2 DNA-binding 
domains. Cartoon representation of SATB2 interacting with chromatin in 
vivo. This model shows the binding of CUT1 as an initiating and stabilizing 
event and CUT2 binding with an antagonistic or destabilizing event that 
promotes mobility of SATB2 within the nucleus. Uncertainty remains 
regarding the role of the HOX domain and whether the chromatin that 
binds to CUT1 and CUT2 is in cis or in trans with each other. The regions 
of the protein that mediate matrix attachment are not well defined, but a 
variant between the CUT2 and HOX domains appears to result in a reduced 
proportion of the SATB2 being matrix-attached.
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Genetics in medicine
8Bengani et al  |  Consequences of disease-associated de novo mutations in SATB2Original research article
it also seems to play a role in establishing higher-order chro-
matin structure,28 suggesting a more fundamental role in com-
plex transcriptional control. There is very little known about 
how the three DNA-binding domains in SATB2 cooperatively 
function; however, it is not clear whether they bind DNA in cis 
or in trans with each other. For this reason, we were particu-
larly interested in the natural experiments that are represented 
within the mutations reported here. The missense variants 
identified within the core of the CUT domain are very likely 
to result in loss of DNA-binding activity given the predicted 
effect on the helical structure of the domain. By comparing the 
effect of mutations in CUT1 and CUT2, we hoped to be able to 
clarify the role of each. However, the results were surprising. 
The mutation in CUT1 resulted in a marked increase in mobil-
ity of the tagged protein, suggesting that this domain is required 
to initiate interaction with chromatin. Mutations in CUT2 (and 
the region between CUT2 and HOX) had the opposite effect, 
suggesting that this domain is required to facilitate dissociation 
of SATB2 from bound chromatin. Taking these data together, 
one possible explanation is that deviation from the normal 
structure of the C-terminal region results in dramatic changes 
in the kinetics of chromatin association and that this mimics 
the complete loss-of-protein function (Figure 4).
It is likely that the number of individuals with SATB2-
associated disorder will increase dramatically over the next few 
years with the wider use of diagnostic sequencing. In addition 
to the obvious benefits to our understanding of the clinical con-
sequences of SATB2 loss of function, the variants themselves 
should provide useful information that will aid in understand-
ing the basic biology of SATB2 function.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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